2026年1月12日，第四十四届摩根大通医疗健康大会在美国旧金山召开，当全球生物医药界的目光聚焦 于该会议时，大洋彼岸的中国接连传来重磅消息。 荣昌生物（SH688331，股价103.34元，市值582.54亿元）率先宣布与全球制药巨头——艾伯维集团控股 公司（以下简称艾伯维）达成56亿美元授权协议，其PD-1/VEGF双抗——RC148成功"出海"；几乎在同 一时间，康方生物（HK09926，股价123.40港元，市值1137.00亿港元）海外伙伴Summit Therapeutics宣 布，依沃西单抗已向FDA（美国食品药品监督管理局）递交上市申请。 这不仅是中国创新药"出海"的标志事件，更意味着中国双抗药物从"跟随者"向"领跑者"的历史性跨越。 然而，近日，宜明昂科（宜明昂科-B，HK01541，股价6.67港元，市值28.78亿港元）终止与美国生物技 术公司Instil Bio（TIL.US）旗下子公司Axion Bio的许可与合作协议，也给国内创新药出海起到一定的 警示作用。 有业内观点指出，这一事件反映出，在全球化征途中，中国创新药企业面临两大挑战：其一，并非所有 闪耀的临床前数据都能转化为临床进 ...

今日上榜个股中，阿里巴巴-W、腾讯控股、小米集团-W等7只股同时上榜港股通（深）、港股通 （沪）成交活跃股， 阿里巴巴-W合计成交额139.06亿港元，成交净买入10.71亿港元，腾讯控股合计成 交额52.93亿港元，成交净买入7.56亿港元。中芯国际合计成交额40.84亿港元，成交净卖出8.35亿港元， 晶泰控股合计成交额30.83亿港元，成交净卖出3.35亿港元。 | 代码 | 简称 | 成交金额（万港元） | 成交净买入（万港元） | 今日涨跌幅（%） | | --- | --- | --- | --- | --- | | 09988 | 阿里巴巴-W | 1390624.57 | 107063.04 | 3.63 | | 00700 | 腾讯控股 | 529333.57 | 75580.19 | 0.72 | | 01810 | 小米集团-W | 496235.12 | 60709.65 | -1.96 | | 00883 | 中国海洋石油 | 121633.02 | 20875.89 | 2.58 | | 01024 | 快手-W | 271128.50 | 7110.07 | -2.24 | | ...

每经记者｜陈星 每经编辑｜陈俊杰 2026年1月12日，当全球生物医药界的目光聚焦于旧金山第44届摩根大通医疗健康大会时，大洋彼岸的 中国接连传来重磅消息——这一天，堪称"中国双抗之夜"。 荣昌生物率先宣布与全球制药巨头艾伯维达成56亿美元授权协议，其PD-1/VEGF双抗RC148成功出海； 几乎同一时间，康方生物海外伙伴Summit宣布，依沃西单抗已向FDA（美国食药监局）递交上市申 请，剑指2026年获批。 这些突破不仅再创中国原创新药"出海"标志事件，更标志着中国双抗药物从"跟随者"向"领跑者"的历史 性跨越。 然而，在热潮之下，宜明昂科的合作终止事件也敲响了警钟，这一事件折射出中国创新药企在全球化征 途中面临的两大挑战：其一，并非所有闪耀的临床前数据都能转化为临床进度和商业价值，合作方的财 力与执行力已成为比交易金额更关键的变量；其二，在PD-1/VEGF这条黄金赛道上，资本与巨头正加速 向头部寥寥数款已被验证的"赢家"集中，而同质化项目则可能面临"沉默的淘汰"。 1月12日，第44届摩根大通（JPM）医疗健康大会在美国旧金山召开，作为参会的中国药企之一，荣昌 生物当天公布了2026年首则BD（商务 ...

深港通（南向）十大活跃成交公司 | 公司名称 | 成交金额 | 净买入额 | | --- | --- | --- | | 阿里巴巴-W(09988) | 58.01 亿元 | +11.61 亿元 | | 腾讯控股(00700) | 23.48 亿元 | +7.49 亿元 | | 小米集团-W(01810) | 21.05 亿元 | +2.83 亿元 | | 中芯国际(00981) | 18.13 亿元 | -6.61 亿元 | | 快手-W(01024) | 12.21 亿元 | +1.14 亿元 | | 美团-W(03690) | 12.18 亿元 | -9076.20 万元 | | 晶泰控股(02228) | 11.69 亿元 | -1933.72 万元 | | 金风科技(02208) | 8.90 亿元 | -8525.00 万元 | | 药明生物(02269) | 8.44 亿元 | -3.47 亿元 | | 康方生物(09926) | 8.26 亿元 | -1.13 亿元 | 智通财经APP获悉，2026年1月13日当天，阿里巴巴-W(09988)、腾讯控股(00700)、小米集团-W(01810) ...

人民财讯1月13日电，1月12日，康方生物自主研发的全球首创PD-1/VEGF双抗依沃西海外合作伙伴 Summit Therapeutics宣布，已于2025年第四季度向美国食品药品监督管理局(FDA)提交了依沃西的一项 生物制品许可申请(BLA)，用于联合化疗治疗第三代EGFR-TKI治疗进展的EGFR突变的非鳞状非小细胞 肺癌(NSCLC)。此次BLA是基于全球III期HARMONi试验的整体结果。根据FDA审评时间表，有望在 2026年第四季度获得FDA的审评决定。 ...

港股开盘，恒生科技指数涨1.93%，恒生指数涨1.32%。个股方面，兆易创新涨45.06%，达力普控股涨 13.35%，荣昌生物涨8.84%，MINIMAX-WP涨6.78%，金山云涨5.86%；时代天使跌4.96%，康师傅控股 跌4.18%，中集安瑞科跌3.72%，康方生物跌3.41%。 本文源自：金融界AI电报 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Insights - The pharmaceutical index rose by 7.81% from January 5 to January 9, outperforming the CSI 300 index by 5.03%. The brain-machine interface and AI medical sectors are expected to remain active in Q1 2026, with a strong rebound in innovative drugs, particularly small nucleic acids [5][25] - The report highlights the potential for significant advancements in small nucleic acids in 2026, driven by breakthroughs in liver-targeted delivery technologies and a surge in clinical data readouts [8][22] - The report emphasizes the importance of selecting innovative drug stocks with strong fundamentals and suggests focusing on companies that have undergone sufficient adjustments [5][49] Summary by Sections Industry Performance - The pharmaceutical index saw 443 stocks rise and 25 fall during the week, with notable gainers including Innovative Medical (+61.04%) and Sanbo Brain Science (+56.15%). Conversely, Baohua Pharmaceutical saw a decline of -21.65% [5][26][27] Small Nucleic Acids - 2026 is projected to be a pivotal year for the small nucleic acid sector, with advancements in liver-targeted delivery technologies and a high frequency of clinical data readouts expected [8][22] - Arrowhead's delivery platform has shown promising results in clinical trials, validating the feasibility of RNAi therapies for obesity and other conditions [9][11] Investment Recommendations - The report suggests focusing on companies with leading platform capabilities and differentiated pipeline layouts, such as Rebio Biotech, Yuyuan Pharmaceutical, and Frontier Biotech [20][24] - It also recommends a diversified investment approach, including innovative drugs, brain-machine interfaces, and AI medical technologies [47][48] Market Trends - The report notes that the aging population and increasing healthcare demands are driving growth in the pharmaceutical sector, with a focus on chronic diseases and innovative medical technologies [47] - The report highlights the ongoing trend of domestic companies enhancing their capabilities in the global market, particularly in innovative drug development and medical devices [46][47] Key Companies to Watch - Recommended stocks include China National Pharmaceutical Group, Rebio Biotech, Shanghai Yizhong, and Yuyuan Medical [49]

Group 1 - The Hong Kong Stock Exchange (HKEX) will launch six new stock options on January 19, 2026, expanding the stock options market and providing investors with more choices [2] - The new stock options will include Zijin Mining International (02259), WuXi AppTec (02359), BeiGene (06160), Lao Poo Gold (06181), Horizon Robotics (09660), and CanSino Biologics (09926) [2] - The average daily trading volume of the derivatives market at HKEX reached a record high of 1,662,751 contracts last year, representing a 7% year-on-year increase [2] Group 2 - Stock options, including monthly and weekly expiry contracts, were among the most actively traded products, with an average daily trading volume of 879,831 contracts, marking a 22% year-on-year increase [2] - The new stock options will have varying contract sizes, such as 200 shares for Zijin Mining International and BeiGene, and 500 shares for WuXi AppTec [3] - The launch will include contracts for multiple months in 2026, specifically January, February, March, April, June, September, and December for certain stocks [3]

Core Viewpoint - Hong Kong Stock Exchange (HKEX) will launch six new stock options on January 19, 2026, expanding the stock options market and providing investors with more choices [1] Group 1: New Stock Options - The new stock options will include Zijin Gold International (02259), WuXi AppTec (02359), BeiGene (06160), Lao Poo Gold (06181), Horizon Robotics (09660), and CanSino Biologics (09926) [1] - The contract sizes for the new options are as follows: Zijin Gold International (200 shares), WuXi AppTec (500 shares), BeiGene (200 shares), Lao Poo Gold (100 shares), Horizon Robotics (3,000 shares), and CanSino Biologics (1,000 shares) [2] Group 2: Market Performance - The average daily trading volume of HKEX's derivatives market reached 1,662,751 contracts last year, marking a 7% year-on-year increase and setting a new record [1] - Stock options, including monthly and weekly expiry contracts, were among the most actively traded products, with an average daily trading volume of 879,831 contracts, a 22% year-on-year increase and a new record high [1]

截至2026年1月9日 13:15，创新药ETF天弘(517380)盘中换手2.54%，成交4041.23万元。跟踪的恒生沪深港创新药精选50指数 (HSSSHID)一度跌超1.5%，随后反转拉升翻红。成分股药明合联(02268)上涨3.14%，迪哲医药(688192)上涨2.92%，皓元医药 (688131)上涨2.48%，绿叶制药(02186)上涨2.03%，美迪西(688202)上涨1.89%。 拉长时间看，截至1月8日，创新药ETF天弘(517380)最新规模达15.97亿元，最新份额达19.80亿份，创成立以来新高。 从资金净流入方面来看，创新药ETF天弘(517380)近3天获得连续资金净流入，最高单日获得8941.75万元净流入，合计"吸 金"1.15亿元。 【产品亮点】 创新药ETF天弘(517380)，对应场外联接基金(A类：014564；C类：014565)。 【机构观点】 万联证券指出，2025年FDA批准新药的创新"质量"提升和技术平台多元化，国内药企崭露头角。建议聚焦前沿技术平台，重点 关注拥有ADC、siRNA、细胞基因治疗（CGT）等前沿技术平台的公司；建议布局具有"出海"潜力的 ...